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Abstract 
Infectious diseases are one of the leading causes of death worldwide. Modelling and understanding 
human infection is imperative to developing treatments to reduce the global burden of infectious 
disease. Bioluminescence imaging is a highly sensitive, non-invasive technique based on the detection 
of light, produced by luciferase-catalysed reactions. In the study of infectious disease, 
bioluminescence imaging is a well-established technique; it can be used to detect, localize and 
quantify specific immune cells, pathogens or immunological processes. This enables longitudinal 
studies in which the spectrum of the disease process and its response to therapies can be monitored. 
Light producing transgenic rodents are emerging as key tools in the study of host response to infection. 
Here, we review the strategies for identifying biological processes in vivo, including the technology of 
bioluminescence imaging and illustrate how this technique is shedding light on the host-pathogen 
relationship.  
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1 Introduction 
Bioluminescence imaging (BLI) is a powerful technology for studying microbial pathogenesis, immune 
response to infection and the effectiveness of anti-infective therapy. It has gained popularity, because 
unlike conventional methods which require the analysis of multiple cohorts of animals at different 
time points, BLI allows for continual analysis in the same cohort. Continual BLI for pathogen 
colonization and treatment response is a well-established tool but its use in determining how animals 
respond to infection is an emerging technology. Reporter genes are invaluable for studying cellular 
immune responses in vivo. They can be used, for example, to monitor specific inflammatory signalling 
pathways and immune cell recruitment to areas of infection. This review explores the numerous 
strategies for identifying biological processes in vivo and how the use of bioluminescent pathogens 
and the luciferase enzyme reporter is being applied to the study of host response to infection. 
2 Models of infectious disease 
Infectious diseases are one of the leading causes of death worldwide, accounting for over 15% of 
global mortality, according to the WHO [1]. Therefore, modelling human infection is imperative to 
understanding and developing treatments to reduce the global burden of infectious disease. Disease 
models of infection include in vitro modelling in cultured cells, in vivo animal models as well as ex vivo 
models of human organs or organoids [2–5]. Today, rodents account for the majority of models used 
in infectious disease research and they model a wide range of infectious disease agents [6]. 
To determine infection and the host response to infection using traditional disease models of 
infection, conventional markers such as blood samples or swabs are taken. The infected animals may 
then be sacrificed at defined time points and infected tissues harvested. An example of subsequent 
analysis is serial plating and colony counting to estimate pathogen numbers and to determine 
localisation. This whole process is highly invasive, end-point analysis intensive and expensive. To 
address this invasive and time-consuming process, imaging and reporter genes have been employed 
for use in in situ detection of specific infectious pathogens and inflammation as well as gene activities 
responsible for the immune response. The use of reporter genes provides a means of expedient, 
simple and highly-sensitive endpoint analysis compared to conventional infection markers. 
3 Pre-clinical imaging modalities in infectious disease research 
Pre-clinical imaging modalities are integral to translational research and they constitute a means of 
assessing biological structures and processes using non-invasive techniques. They enable longitudinal 
studies in individual animals. A main advantage is the reduction of biological variability as each animal 
can function as its own control. These imaging modalities also support two of the 3Rs of animal 
research; reduction and refinement, by minimising numbers of animals sacrificed and the intrinsic 
non-invasive nature of imaging which help to improve animal welfare [7]. Numerous non-invasive 
imaging modalities have been used for infectious disease research as discussed below. 
Positron emission tomography (PET) labels biologically active molecules with positron-emitting 
radioisotopes to image in vivo pathophysiological processes. Using the clinically-established 18F-FDG 
as a surrogate marker for infection-induced inflammation it was possible to monitor response to 
Staphylococcus aureus vascular graft infection [8]. Following tuberculous meningitis infection in a 
young rabbit model, activated immune cells in the brain were detected non-invasively using the 124I-
DPA-713 radio-isotope tracer [9].  
Single photon emission computed tomography (SPECT), is a similar imaging modality to PET, whereby 
administered radioisotopes emit gamma radiation. SPECT combines multiple images to create a 3-
dimensional image. It has an established role in the imaging of myocardial and cerebral perfusion but 
its role in infection is evolving. For example, the radioisotope, [99mTc]annexin V-128, is an in vivo 
marker of cellular stress and apoptosis, and can be used to detect and trace bacterial infection and 
response to treatment by SPECT imaging [10]. 
Computed tomography (CT) uses X-rays to measure and compare differences in tissue densities. It is 
helpful in detecting tissue or organ morphological changes caused by infection and inflammation, such 
as pulmonary fibrosis [11]. 
Magnetic resonance imaging (MRI) is a non-ionizing 3D imaging modality that uses the magnetic 
properties of tissues and their interactions with external magnetic fields. MRI not only provides 
anatomical information but it can also provide physiological data such as organ perfusion, molecule 
diffusion and tissue chemical composition [12]. Unsurprisingly MRI is an important tool in infectious 
disease research and has been used in multiple ways including the monitoring of inflammation[13], 
the quantification of blood flow to infected sites [8] and the imaging of host abscess formation [14]. 
Photoacoustic tomography works on the natural property of tissues to thermoelastically expand when 
stimulated with pulsed laser. This leads to ultrasound waves being emitted from the tissues which can 
be detected using an ultrasound transducer. It produces real-time high resolution scans and 3D 
reconstructions [15]. Its use in infectious disease research is limited but recently a new photoacoustic 
contrast agent that is highly specific for detecting certain bacteria in vivo has been described [16].  
Optical imaging includes a variety of imaging techniques that rely on light production in the visible, 
ultraviolet or infrared electromagnetic spectrum. These optical imaging modalities usually require 
suitable reporter genes to be tagged in cells or pathogens of interest. The most relevant to infectious 
disease research are BLI, fluorescence imaging and two-photon intravital microscopy. Two-photon 
intravital microscopy, for example, contributed to detection of a pathway involved in the intravascular 
coagulation process which occurs during sepsis [17].  
4 Conventional reporter gene methods  
Monitoring biological processes in vivo is challenging therefore reporter genes may be used as 
surrogate markers to localise and quantify molecular signals. This technology relies upon the control 
of reporter genes by selected regulatory sequences; this confers the organism with a marker that can 
be easily detected and quantified, such as luminescence or fluorescence. 
Numerous reporters have been developed. The first to be exploited were the bacterial enzymes 
chloramphenicol acetyltransferase (CAT) and beta-galactosidase (β-gal). CAT catalyses the transfer of 
the acetyl group from acetyl-coenzyme A to chloramphenicol [18]. Its popularity is limited by the need 
for radioisotopes and relatively elaborate purification and enzymatic assays to detect CAT reporter 
expression. β-gal, which recognises and cleaves X-gal to generate an intense blue stain, was first 
described by Jacob and Monod [19]. β-gal, the enzyme encoded by the LacZ gene in E.coli, became 
one of the most commonly used reporter genes for quantifying gene promoter activity [20].  
These reporters have now been superseded by fluorescent markers. This began with the cloning of 
green fluorescent protein (GFP) in the 80s and the development of enhanced mutants of GFP [21–23]. 
The two best characterised GFPs are from the marine invertebrates; Aeqourea victoria and Renilla 
reniformis. Other GFP-like green, yellow and red proteins have been subsequently cloned [24]. The 
great advantage of these GFP-like proteins is their ability to form internal fluorophores without 
requiring accessory enzymes or substrates. They are also highly stable and are non-toxic in most cases. 
They are widely used to visualise transcriptional activities of promoters and to locate proteins in live 
cells [25].  
4.1 Disadvantages of conventional reporter gene methods 
Conventional assays of host–pathogen interactions require that experimental animals be euthanized 
at multiple time points to analyse the response to infection. While this approach has been, and 
remains invaluable in deﬁning key aspects of microbial pathogenesis, there are limitations to these 
methodologies. Analysing individual animals at single time points precludes real-time monitoring of 
spatial and temporal progression of infection in the same animal, which may reveal biologically 
relevant variations. Furthermore, host response at an unexpected site of infection may be missed 
because the tissue is not harvested and analysed (the “Streetlight effect”). Finally, conventional assays 
of pathogenesis typically require large numbers of animals to obtain statistically meaningful data at 
multiple time points. 
Fluorescence-based optical imaging is impeded by light absorption in tissues. Haemoglobin absorbs 
light with a peak absorbance of 575nm whilst water absorbs light with a peak absorbance of 977nm, 
leaving an optimal optical window between these two wavelengths [26]. GFP is not an ideal 
fluorophore for in vivo imaging since its excitation and emission peak wavelengths are 488nm and 
509nm, respectively [27]. Autofluorescence from the tissue is also often problematic as it interferes 
with fluorescent signals in the green spectrum leading to high background fluorescent levels.  
Transgenic fluorophores may also elicit immune responses in immune competent organisms. GFP has 
been shown to induce T-cell mediated immunogenicity in numerous mouse strains, thus limiting its 
application as a surrogate marker for immunological processes [28–30].  
5 BLI and luciferase enzymes as reporter genes 
Light is emitted when luciferase enzymes catalyse their substrates in vivo. BLI detects this light as a 
surrogate marker for protein expression using comparatively inexpensive charge-coupled device (CCD) 
cameras. Luciferase reporter genes have gained popularity in recent years because of their ability to 
quantify promoter activation with greater fidelity compared with conventional reporter genes. This is 
supported by the dramatic increase in luciferase-associated citations over the past twenty years 
(Figure 1). It can be used to detect, localize and quantify specific immune cells, pathogens or 
immunological processes.  
The luciferase enzyme from the firefly, Photinus pyralis, was the first to be cloned and characterised 
[31]. Firefly luciferase catalyses an oxidative reaction in the presence of its substrate D-Luciferin and 
adenosine triphosphate, magnesium and oxygen. The production of oxyluciferin releases a photon of 
light. Firefly luciferase is a good biomarker reporter as it requires no post-translational modifications, 
it has a half-life of approximately 3 hours and it has a relatively red-shifted emission spectrum [32,33]. 
Subsequently, luciferase enzymes have been cloned from other organisms including from the sea 
pansy Renilla reniformis, the click beetle Pyrophorus plagiophthalamus, the copepod Gaussia princeps 
and the jellyfish Aequorea victoria amongst others. Coelenterazine is the substrate for Renilla and 
Gaussia luciferases in a reaction which leads to flash kinetics in vivo with rapid onset and significant 
diminution of bioluminescence after 10 seconds [34]. The blue-green light emission penetrates 
mammalian tissue poorly, compared with firefly luciferase, although a red-shifted Renilla luciferase 
mutant has subsequently been developed [35,36].  
Other luciferase enzymes that are particularly important in animal infection models are those from 
the luxCDABE operon in bacteria such as Photorhabdus luminescens and Xenorhabdus luminescens.  
The bacterial lux operon encodes enzymes that oxidise a long-chain aldehyde and a reduced flavin 
mononucleotide to produce oxidised flavin which emits light at 490nm [37]. This reaction is catalysed 
by a bacterial luciferase which is encoded by the luxA and luxB genes. The luxC, luxD and luxE genes 
encode a multienzyme complex which is responsible for the regeneration of the aldehyde substrate 
from the fatty acid produced by the initial reaction. The main advantage of the lux operon system is 
the ability to express the enzymes that synthesise the substrate, therefore addition of exogenous 
substrate is unnecessary. The lux operon has been transferred to other bacterial strains to confer them 
with bioluminescence. 
BLI has several advantages over the conventional reporter gene methods described above. While in 
vivo imaging has been successfully performed with different fluorescent proteins [38], the signal to 
background ratio is notably greater with luciferase BLI [39]. It is also an extremely sensitive assay and 
it can be performed multiple times on a single animal [40]. This helps to reduce variation between 
animals and it eliminates the costly and time-consuming task of gathering data through sequential 
sacrificing of animals at different time points. Compared with other imaging strategies it is also quick 
and easy to use, it is less expensive and it has minimal post-image analysis. 
6 BLI and its use in monitoring host response to infection 
Luciferase BLI is now well-established in the field of infectious disease research. It has been commonly 
used to study colonization of pathogens, to monitor microbial gene expression, for example genes 
involved in virulence, as well as to test treatment and vaccine efficacy [41]. BLI’s role in examining the 
host response to infection is an emerging field and there are three main ways that it can be used to 
examine host response to infection: 
1. Bioluminescent pathogens: Using bioluminescent pathogens to infect animals with an 
altered immune system. 
2. Light-producing transgenic reporter animal: Delivering a luciferase reporter gene under the 
control of a promoter or a transcription factor binding sequence of interest. 
3. Light-producing immune cells: Tracking luciferase-reporter immune cells. 
6.1 Bioluminescent pathogens 
Two different strategies have been applied for engineering bioluminescent pathogens. The first 
strategy is using the luxCDABE operon from bacteria such as Photorhabdus luminescens or 
Xenorhabdus luminescens which is transferred to other bacteria to confer them with constitutive 
bioluminescence. The second strategy, which is mainly employed to create bioluminescent viruses and 
fungi, uses recombinant pathogens engineered to express a luciferase reporter gene, for example 
herpes simplex-1 luciferase reporter virus [42]. 
Bioluminescent pathogens can be used to infect animals that have an altered immune system to give 
insight into how the hosts immune system responds to infection. Neonates and young children are 
known to have an increased susceptibility to infection owing to a lack of protective immune responses 
by their immature immune system. To study the mechanisms behind neonatal susceptibility to 
infection, a bioluminescent Salmonella typhmurium strain was used to infect mice at different ages to 
monitor infectivity and systemic infection [43]. As expected, younger mice, with a less mature immune 
system, were more vulnerable to severe systemic infection; this susceptibility decreased with age. 
Similarly, a bioluminescent Staphylococcus epidermidis strain was used to infect mice to model 
indwelling medical device-related infections. Immune compromised mice were more susceptible to 
these device-related nosocomial biofilm infections than wild type mice [44]. 
Bioluminescent bacteria have also been used to study specific aspects of the host immune system by 
infecting mice in which immune-related genes have been genetically disrupted.  Toll-like receptors 
(TLRs), an integral part of the innate immune system, recognise microbes by binding to specific 
pathogen-associated molecular patterns and in response they activate appropriate innate immune 
defences. TLR 2 and 4 knock-out mice (Tlr2/4-/- mice) were found to be particularly susceptible to lung 
infection by a bioluminescent strain of flagellin-deficient Pseudomonas aeruginosa [45]. This 
demonstrates the important role of the TLRs in mounting a sufficient host innate immune response to 
control bacterial infectivity. 
Myeloid differentiation primary response protein (MyD88), another important innate immune system 
protein, acts as a signal transducing adaptor protein. Upon activation of TLRs by their specific ligand, 
MyD88 is recruited and leads to a propagation of downstream signalling pathways that results in 
activation of numerous pro-inflammatory transcription factors including NF-κB. MyD88-/- mice 
exhibited increased susceptibility to lethal colitis when infected with a bioluminescent strain of 
Citrobacter rodentium [46]. This highlights the key role of MyD88 and NF-κB in mediating host defence 
against enteric pathogens. 
Interferons(IFN) have a significant role in mediating the host innate immune response to pathogens, 
in particular to viruses [47,48]. Mice lacking different IFN receptors were infected with herpes simplex 
virus-1 (HSV-1) carrying the firefly luciferase reporter virus.  BLI revealed widespread and, ultimately 
lethal, dissemination in Type 1 and Type 2 IFN receptor knock-out mice; this illustrated the importance 
of these receptors in limiting HSV-1 infectivity and dissemination [42]. 
6.2 Light-producing transgenic (LPT) reporter rodents 
Infection elicits numerous signalling pathways which initiate and control the inflammatory response 
including local cytokine production and recruitment of immune cells to the site of infection. Many of 
these responses are controlled at the transcriptional level and so reporter mice have been generated 
using a promoter or a transcription factor binding site sequence for the gene of interest controlling 
luciferase transgene expression.  
6.2.1 Germline LPT reporter rodents 
Light producing transgenic rodents have been generated, conventionally, using germline transgenic 
technology. This is useful in that every cell in the mouse containing the specific genetic biosensor 
which enables whole body transcriptional activity to be monitored by continual BLI. Germline LPT 
reporter mice that have been used in the study of immune response to infection are described below. 
LPT interferon-β reporter mouse 
Type 1 interferons are important mediators of the host immune response to infection [49]. They are 
also believed to have a role in the non-infected state by priming immune cells to enable them to 
respond to infections in a timely manner [48]. Interferon-β, part of the large type 1 interferon family, 
is considered the master regulator of the type-1 interferon signalling pathway [50]. 
Germline LPT interferon-β mice were developed in which cre-recombinase was used to replace the 
interferon-β gene with a firefly luciferase reporter transgene. Therefore these mice expressed 
luciferase under the control of the endogenous interferon-β promoter. The luciferase surrogate of 
interferon-β expression was determined following influenza A and La Crosse viral infections. This 
mouse was also used to detect constitutional expression of interferon-β, and specifically found that 
the thymus is responsible for non-infective interferon-β expression [51]. 
LPT interleukin-1β reporter mouse 
Interleukin- 1β is a potent mediator of infection and the pro-inflammatory response. It is responsible 
for a wide range of infection-related reactions including fever, hypotension and the production of 
other pro-inflammatory cytokines. A germline transgenic interleukin-1β reporter mouse was 
developed which firefly luciferase was placed under the control of a 4.5kb fragment of the human 
interleukin-1β promoter. Luciferase activity was increased in this mouse following systemic LPS 
administration. This activity was found to be suppressed with the anti-inflammatory agent 
dexamethasone [52]. 
LPT CCL20 reporter mouse 
Chemokines play an important role in the chemotactic movement of immune cells to areas of infection 
and inflammation. CCL20 is a major constitutive chemokine which is crucial in recruiting immune cells 
to mucosal lymphoid tissues such as Peyer’s patches and tonsils [53]. It also has a significant role as 
an inducible chemokine to promote migration of immune cells to areas of infection and inflammation 
[54].  A LPT CCL20 reporter mouse was created by incorporating a mouse CCL20 promoter upstream 
of the firefly luciferase transgene [55]. The luciferase activity was used as a surrogate for CCL20 
expression in the mouse after systemic administration of flagellin (a major constituent of bacterial 
flagella) and heat-inactivated salmonella. Luciferase activity was comparable to that seen with a 
germline LPT NF-κB reporter mouse. The results from these two strains led the authors to conclude 
that NF-κB was an important transcriptional activator of CCL20 expression [56]. 
LPT inducible nitric oxide synthase (iNOS) reporter mouse 
iNOS is an inducible enzyme that catalyses the production of nitric oxide from L-arginine. It is produced 
by many different cell types and plays an important role in infection and inflammation [57]. iNOS-
mediated release of nitric oxide is important in the pathogenesis of septic shock whereby it leads to 
systemic hypotension and myocardial depression [58]. A germline LPT iNOS mouse containing firefly 
luciferase under the control of murine iNOS promoter showed significantly increased liver luciferase 
activity upon interferon-ϒ and LPS induction of sepsis. In inflamed joints in a model of acute septic 
arthritis, elevated luciferase was significantly reduced by the administration of the anti-inflammatory 
steroid dexamethasone. This illustrates the utility of such models in validating new therapeutic 
compounds in a range of inflammatory models [59]. 
LPT glial fibrillary acidic protein (GFAP) reporter mouse 
Astrocytes are a diverse sub-type of glial cells found in the central nervous system. They have 
numerous functions but their role in providing defence against brain insults appears to be an 
important one [60,61]. GFAP is a major intermediate filament protein used as a marker to distinguish 
astrocytes from other cells in the central nervous system [62]. 
Germline LPT GFAP reporter mice have been generated in which firefly luciferase is controlled by a 
fragment of the GFAP promoter. Kadurugamuwa et al. generated a mouse where firefly luciferase was 
transcriptionally regulated by a 12kb GFAP promoter fragment [63]. They used this in combination 
with Streptococcus pnemoniae containing the lux operon to study host and pathogen responses in a 
model of meningitis. Since firefly luciferase and lux operon have distinct emission spectra, they were 
able to correlate the progression of bacterial meningitis with astrocyte activation in the CNS. 
Importantly they found that early administration of antibiotics was sufficient to prevent neuronal 
injury. Cho and colleagues produced a transgenic mouse in which firefly luciferase was 
transcriptionally regulated by a 2.2kb fragment of the GFAP promoter [64]. They generated a second 
strain in which Renilla luciferase was placed under transcriptional control of a 0.5kb fragment of the 
promoter of the housekeeping gene Glyceraldhehyde 3-phosphate dehydrogenase. Crossing these 
strains produced a dual transgenic reporter mouse where neuroinflammation, induced by kainic acid 
administration, could be monitored by firefly luciferase and in which the signal could be normalised 
against the Renilla luciferase.  
LPT NF-κB reporter mice 
Luciferase reporters are widely used for the study of promoter activity but the more recent design of 
synthetic transcription factor binding elements has enabled targeted interrogation of gene and 
transcriptional factor relationships. These consist of serial transcription factor binding consensus 
sequences upstream of a minimal polymerase initiating sequence which drive luciferase expression. 
For example, this technology has been developed for the NF-κB transcription factor whose canonical 
NF-κB genomic binding site has been defined as 5’-GGGACTTTC-3’ [65]. 
NF-κB regulates the expression of genes responsible for many cellular processes including immune 
and inflammatory pathways. These proteins are ordinarily bound and inhibited by IκB. However, 
following infection or the release of pro-inflammatory cytokines, there is activation of IκB kinase which 
leads to the phosphorylation of IκB and subsequent ubiquination and proteasomal degradation [66]. 
Free NF-κB dimers are therefore able to translocate to the nucleus where they bind directly with the 
consensus DNA sequence in the promoter of NF-κB target genes to initiate an inflammatory response 
[67]. 
Germline LPT rodents have been produced in which luciferase expression is a surrogate marker for 
NF-κB transcriptional activity [68,69]. Yull et al. produced mice in which the NF-κB-dependent portion 
sites of the HIV-1 long terminal repeat was used to drive luciferase expression [69]. These mice showed 
NF-κB dependent luciferase activity in the lung, liver, spleen, kidneys and forebrain after 
intraperitoneal lipopolysaccharide (IP LPS). This technology was also used to assess potential anti-
inflammatory therapeutic options including an IκB kinase inhibitor which successfully inhibited pro-
inflammatory NF-κB dependent luciferase activity [68]. A similar transgenic model was developed to 
monitor NF-κB activity following systemic LPS administration as well as TNF-α and IL-1α cytokine 
administration[70]. In this case, the transgenic mouse contained luciferase under the transcriptional 
control of a triplet repeat of a consensus NF-κB. 
Kielland et al. developed transgenic mice using a novel bidirectional promoter regulated by a 
sextuplicate repeat of consensus NF-κB binding elements driving both luciferase and enhanced GFP 
transgenes[71]. These mice were used to determine pro-inflammatory NF-κB transcriptional activity 
in the brains of newborn pups injected with intracerebral LPS. 
6.2.2 Somatic LPT reporter rodents 
An advantage of germline LPT rodents is that every cell in the body carries the genetic biosensor. 
However, it is very difficult to monitor activity in individual organs and tissues because of the 
confounding bioluminescence signal in surrounding tissues. The generation of germline transgenics is 
also time-consuming and colonies are both expensive to generate and to maintain.  An alternative 
approach to the germline LPT reporters is using post-natal somatic gene transfer to produce somatic 
transgenic reporter animals. 
Non-viral vector-mediated somatic LPT reporter mouse 
Interleukin-8 is a pro-inflammatory cytokine produced in response to a variety of infective and 
inflammatory stimuli and is an important chemoattractant for immune cells such as neutrophils [72]. 
A mouse model was described in which the luciferase gene under the control of a bovine interleukin-
8 promoter was transiently expressed [73]. Mice received a plasmid containing this expression 
cassette by intra-tracheal administration. Although mice lack an exact homolog of the interleukin-8 
gene, the authors demonstrated that mice possess the transcriptional apparatus to activate the 
bovine interleukin-8 promoter in response to LPS or TNF-α administration for up to 60 days after gene 
delivery. This technology was subsequently used in a cystic fibrosis mouse model to monitor the 
inflammatory response to Pseudomonas aeruginosa infection [74]. 
Viral vector-mediated somatic LPT reporter mice 
In the early 1980s, gene transfer vectors based upon viruses were developed from adenovirus, 
retrovirus and adeno-associated virus [75–77]. Compared with non-viral approaches, viral vectors are 
much more efficient and it is this efficiency which has contributed to their widespread adoption in the 
burgeoning field of gene therapy. They are firmly established as gene-targeting tools in biological 
research. 
Adenoviral vector-mediated generation of somatic LPT rodents 
There have been several studies exploiting adenoviral vectors to make somatic LPT rodents. However, 
since adenoviral vectors often evoke potent immune responses, they have mainly been used in 
profoundly immune-deficient mouse strains which are often not ideal for the study of infection 
[78,79]. 
For the production of somatic LPT rodents, Peterson et al. used adenoviral vectors to deliver NF-κB 
and AP-1 firefly luciferase reporter constructs into distinct central nervous system nuclei [80]. They 
were able to monitor the local NF-κB activity and AP-1 activity in response to systemic LPS 
administration. 
Lentiviral reporter gene production for neonatal somatic LPT mice 
Lentiviral vectors are a subclass of retrovirus, which naturally integrate into dividing and non-dividing 
cells as well as showing stable and long-term expression [81]. Systemic vector delivery in adult rodents 
can evoke an immune response which can not only complicate the transcriptional activity being 
studied but also lead to a loss of transduced cells [82]. Viral vector administration to neonatal rodents 
prior to the full maturation of the immune system may induce immune tolerance to the transgenic 
protein, permitting prolonged expression of the transgene [83,84].  
We have generated liver-, brain- and lung- targeted NF-κB reporter mice using a combination of route 
administration and lentiviral pseudotyping in newborn rodents [85] (Figure 2). We observed that the 
NF-κB reporter was activated directly by TLR4 mediated-signalling since LPS-induced BLI signal was 
completely abolished in Tlr4 -/- mice. The following section describes the method of producing 
lentiviral transcription factor activated luciferase reporters (method 1) and how to use them for 
monitoring transcriptional activity in vivo (method 2). See appendix for materials and equipment. 
Method 1 [85]: Construction and insertion of synthetic transcription factor response element into 
lentiviral reporter gene cassette using Gateway® recombination cloning technology (Figure 
4)  
PCR amplification of firefly luciferase (Fluc) and 2A-eGFP(enhanced-GFP) sequences is performed 
followed by overlap extension PCR to anneal and create a Fluc-2A-eGFP insert. The LNT-Gateway®-
Multiple cloning site plasmid vector (pLNT-GW-MCS) is digested using compatible ends to those 
generated for the insert. The Fluc-2A-eGFP insert is ligated into the digested pLNT-GW-MCS vector.  
A minimal promoter (MP) sequence (the adenoviral E1A minimal promoter was used) flanked by XhoI 
sites is de novo synthesized (Aldevron, Fargo MD, USA). This is then cloned into unique XhoI sites in 
the pENTR-1A Gateway® cloning shuttle vector to produce pENTR-MP. Minimal consensus binding 
sequence are determined for the candidate transcription factor. 5’-GGGACTTTC-3’ is used for the NF-
κB response element [65]. A serial transcription factor binding sequence (TFBS) is designed by 
interspersing 4-10 binding sequences with 10 random nucleotides and then synthesized with 
restriction enzyme sites at the 5’- and 3’- termini (Aldevron, Fargo MD, USA). This TFBS is then cloned 
into pENTR-MP to produce pENTR-TFBS-MP. The TFBS-MP sequences are then recombined into pLNT-
GW-Fluc-2A-eGFP using Gateway® cloning technology.  
In order to produce a high-titre second generation lentivirus a three plasmid system is used [86]. 
Envelope plasmid VSV-G (pMD.G2; Vesicular Somatitis Virus glycoprotein) and the packaging plasmid 
pCMVΔR8.74 containing the gag and pol genes is used. The packaging plasmid allows the lentivirus 
carrying the transgene to integrate into the host genome.  
Method 2 [85]: Neonatal organ-targeted delivery of lentiviral vector  
All in vivo neonatal injections are performed within 24 hours after birth. Neonatal pups are 
anaesthetised on ice. Pups are injected by the following routes and volumes: intracranially (5 μl), 
intravenously (20 μl), subcutaneously (10 μl), intranasally (20 μl), or ventral subcutaneously (5 μl). The 
luciferase reporter activity is monitored in living adult mice by anesthetizing mice with 4% isofluorane 
in 100% O2. 300 μl of D-luciferin solution at a concentration of 15 mg/ml (a dose of approximately 150 
mg/kg) is injected into the intraperitoneal cavity approximately 5 minutes before imaging. The mice 
are imaged in a warmed, light-proof detection chamber in the CCD imager. Images are viewed and 
analysed using the Living Image software (Perkin Elmer, Coventry, UK). 
6.3 Light producing immune cells  
Trafficking of immune cells to areas of infection is an integral part of the host response to infection. 
Technology has been developed to allow for localisation and tracking of certain cells involved in the 
immune response using BLI.  
Akimoto et al. used luciferase as a marker of bone-marrow derived cells to determine their ability to 
cross the blood-brain barrier and differentiate into microglia (the resident macrophages of the brain) 
following LPS administration to the hippocampus [87]. BLI showed increased luciferase activity in the 
brain and these luciferase-expressing cells were confirmed to be microglia. This study successfully 
distinguished between two different types of brain microglia; resident and bone-marrow derived, as 
well as providing a powerful tool for imaging the movement of bone-marrow derived cells. 
An alternative way of using BLI imaging to detect immune cell response in vivo is with luminol 
bioluminescence. Luminol is a redox-sensitive compound that emits blue luminescence upon exposure 
to an appropriate oxidising agent. As luminol is cheap to produce and relatively simple to synthesis it 
is popular in a variety of fields including biochemistry, clinical diagnostics and forensic sciences for 
detecting reactive intermediates. Luminol luminescence has been used to study whole blood and  
phagocytes for many years [88]. Myeloperoxidase is activated during phagocytosis in the azurophilic 
granules of neutrophils and in the lysosomes of macrophages. It is released into phagosomes and 
catalyses the reaction which produces bactericidal hypochlorous acid. [88]. The produced 
hypochlorous acid can directly or indirectly oxidize luminol to produce light (Figure 3). Gross et al. 
developed a method to image myeloperoxidase activity in small laboratory animals in vivo [89]. In a 
focal arthritis model, generated by intra-articular injections of LPS, luminol bioluminescence was 
readily detected from LPS-treated joints allowing tracking of activated phagocytes to areas of infection 
[90]. 
7 Conclusions 
The use of BLI is becoming widespread for infectious disease research as it avoids many of the 
problems associated with conventional research methods. BLI is becoming a useful technology for 
monitoring host response to infection. In the future, the use of optical imaging modalities in 
combination with other imaging modalities may further help us to understand the complexities of the 
host pathogen relationship. 
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10 Appendix  
 
10.1 List of materials and Equipment 
 Primers and template to amplify reporter gene  
 High-fidelity polymerase 
 DNTPs 
 PCR cleanup kit 
 1.5% agarose gel 
 Gel extraction kit 
 Xho I, Mlu I and BamHI restriction enzymes 
 Quick Ligase 
 SOC outgrowth media 
 ccdB resistant competent cells such as DB3.1 or One Shot® ccdB Survival™ 2 T1R Competent 
Cells 
 Luria broth (LB) 
 Ampicillin (100 μg/ml) 
 Plasmid DNA mini-prep kit 
 WPRE reverse primer for sequencing 
 De novo synthesis of minimal promoter and synthetic promoter DNA (Aldevron, ND, USA) 
 TOP10, DH5α or similar regular cloning competent cells 
 LB containing kanamycin antibiotic (50 μg/ml) 
 Plasmid DNA mini-prep kit 
 pENTR-1A (Invitrogen, UK) 
 Buffer TE (pH 8.0)  
 LR clonase II ™ (Invitrogen, UK)  
 Proteinase K 
 Stbl3 competent cells   
 Highly proliferating, mycoplasma-free HEK293T cells  
 OptiMem® I reduced-serum medium (Gibco, UK) 
 Phosphate buffered saline (PBS) containing calcium and magnesium  
 Vesicular Stomatitis Virus glycoprotein (VSV-g) envelope plasmid (pMD2.G) (Aldevron, Fargo, 
USA) 
 Packaging plasmid containing gag, pol, tat, rev viral genes (pCMVΔR8.74) (Aldevron, Fargo, 
USA) 
 Polyethylenimine transfection reagent (10 mM): 10 ml branched PEI made up to 41.2 ml 
with dH2O (pH 7.0)  
 0.45 µM PVDF sterile filter cups 
 Complete Media:  Dulbecco’s Modified Eagles Media, 10% FBS, 1% penicillin/streptomycin 
 33 gauge Hamilton needle and 100 µl syringe (Fisher Scientific)  
 D-luciferin (Gold Biotechnology) reconstituted in sterile PBS to a working concentration of 15 
mg/Ml 
 27 gauge needle 
 Anaesthetic, 100% Isoflurane inhalation liquid vapor liquid (Abbott)  
 Oxygen - 5.1%, flow rate 1.5 per min 
 IVIS machine (Perkin-Elmer) 
